


PATENT
Docket No. 437252001200

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV335377334US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 17, 2005

Signature: _____

Georgina Matos
Georgina Matos



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of:
Mark ALVIS et al.

Serial No.: 10/082,443

Filing Date: February 22, 2002

For: METHODS AND COMPOSITIONS FOR
IMPROVED ARTICULAR SURGERY
USING COLLAGEN

Examiner: A. Mohamed

Group Art Unit: 1653

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

03/21/2005 SFELEKE1 00000088 031952 10082443

01 FC:1806 180.00 DA

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☒ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.


The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling;
or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **437252001200**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: March 17, 2005

Respectfully submitted,

By 

Kimberly A. Bolin
Registration No.: 44,546
MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304
(650)813-5740

Substitute for form 1449/PTO


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/082,443
Filing Date	February 22, 2002
First Named Inventor	Mark ALVIS
Art Unit	1653
Examiner Name	A. Mohamed
Attorney Docket Number	437252001200

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	RE35748	03-17-1998	Luck et al.	
	2.	RE33375	10-09-1990	Luck et al.	
	3.	4,619,913	10-28-1986	Luck et al.	
	4.	4,774,091	09-27-1988	Yamahira et al.	
	5.	4,789,662	12-06-1988	Thomas-Leurquin et al.	
	6.	4,865,846	09-12-1989	Kaufman	
	7.	4,919,939	04-24-1990	Baker	
	8.	4,923,699	05-08-1990	Kaufman	
	9.	5,024,841	06-18-1991	Chu et al.	
	10.	5,385,738	01-31-1995	Yamahira et al.	
	11.	5,540,912	07-30-1996	Roorda et al.	
	12.	5,760,077	06-02-1998	Shahinian Jr.	
	13.	5,766,631	06-16-1998	Arnold	
	14.	5,902,606	05-11-1999	Wunderlich et al.	
	15.	5,919,473	07-06-1999	Elkhoury	
	16.	5,980,946	11-09-1999	Jones et al.	
	17.	6,165,983	12-26-2000	Klaus	
	18.	6,261,582	07-17-2001	Needham et al.	
	19.	6,350,781	02-26-2002	Shahinia Jr.	
	20.	6,407,088	06-18-2002	Dong et al.	
	21.	6,645,168	11-11-2003	Demopoulos et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	22.	Butterfield, N. et al. (2001). "Combined pre-and post-surgical bupivacaine wound infiltrations decrease opioid requirements after knee ligament reconstruction," <i>Can. J. Anesth.</i> 48(3):245-250.	
	23.	Cepeda, M. et al. (1997). "Intra-articular morphine, intra-articular bupivacaine, or subcutaneous morphine?" <i>Reg Anesth.</i> 22(3):223-238.	
	24.	Creamer, P. et al. (1996). "Pain mechanisms in osteoarthritis of the knee: effect of intraarticular anesthetic," <i>J. Rheumatol.</i> 23:1031-1036.	
	25.	De Andres, J. et al. (1998). "Intra-articular analgesia after arthroscopic knee surgery: comparison of three different regimens," <i>Eur. J. Anaesth.</i> 15:10-15.	

Examiner Signature	Date Considered
--------------------	-----------------

pa-950549



ALTERNATIVE TO PTO/SB/08a/b (06-03)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/082,443
				Filing Date	February 22, 2002
				First Named Inventor	Mark ALVIS
				Art Unit	1653
				Examiner Name	A. Mohamed
Sheet	2	of	2	Attorney Docket Number	437252001200

26.	Debruyne, D. et al. (1985). "Monitoring serum bupivacaine levels during arthroscopy," <i>Eur. J. Clin. Pharmacol.</i> 27:733-735.	
27.	Finegold, H. (Date Unknown). "Applied Pharmacology of Local Anesthetics," located at < http://ramanathans.com/localchapterram[1].htm > visited on January 20, 2005. (7 pages).	
28.	Geutjens, G. et al. (1994). "Analgesic effects of intraarticular bupivacaine after day-case arthroscopy," <i>Arthroscopy</i> 10:299-300.	
29.	Henderson, R. et al. (1990). "Postarthroscopy analgesia with bupivacaine. A prospective, randomized, blinded evaluation," <i>Am. J. Sports Med.</i> 18(6):614-617.	
30.	Kaeding, C. et al. (1990). "Bupivacaine use after knee arthroscopy: pharmacokinetics and pain control study," <i>Arthroscopy</i> 6(1):33-39.	
31.	Liguori, G. et al. (2002). "Possible bupivacaine toxicity after intraarticular injection for postarthroscopic analgesia of the knee: implications of the surgical procedure," <i>Anesth. Analg.</i> 94:1010-1013.	
32.	McGhan Medical Corporation. (2000). "Zyderm® Collagen Implant Physician Package Insert", 2 pages.	
33.	McPherson, J. et al. (1988). "The effects of heparin on the physiochemical properties of reconstituted collagen," <i>Collagen Rel Res</i> 8(1):65-82.	
34.	Meinig, R. et al. (1988). "Plasma bupivacaine levels following single dose intraarticular instillation for arthroscopy," <i>Am. J. Sports Med.</i> 16(3):295-300.	
35.	Purdue Pharm L.P. (1999). "Chirocaine® (Levobupivacaine Injection)" Catalog, 20 pages.	
36.	Rosenblatt, J. et al. (1989). "The effect of collagen fiber size distribution on the release rate of proteins from collagen matrices by diffusion," <i>J. Controlled Release</i> 9:195-203.	
37.	Schroeder-Tefft, J. et al. (1997). "Collagen and heparin matrices for growth factor delivery," <i>J. Controlled Release</i> 49:291-298.	
38.	Smith, I. et al. (1991). "Effects of local anaesthesia on recovery after outpatient arthroscopy," <i>Anesth. Analg.</i> 73:536-539.	
39.	Solanki, D. et al. (1992). "Serum bupivacaine concentrations after intraarticular injection for pain relief after knee arthroscopy," <i>Arthroscopy</i> 8(1):44-47.	
40.	Spivey, W. et al. (1987). "A clinical comparison of lidocaine and bupivacaine," <i>Ann Emerg. Med.</i> 16:752-757.	
41.	Varrassi, G. et al. (1999). "Intra-articular buprenorphine after knee arthroscopy: a randomised, prospective, double-blind study," <i>Acta Anaesthesiol. Scand.</i> 43:51-55.	
42.	Wasudev, G. et al. (1990). "Blood levels of bupivacaine after arthroscopy of the knee joint," <i>Arthroscopy</i> 6(1):40-42.	
43.	Weiker, G. et al. (1991). "Serum lidocaine and bupivacaine levels in local technique knee arthroscopy," <i>Am. J. Sports. Med.</i> 19(5):499-502.	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

pa- 950549